Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
Overview
Latest
Regional
Industry
Featured
Multimedia
Other Languages
Public Company News
All
APAC
Global
All
APAC
Global
All
APAC
Global
All
APAC
Global
{{toptitleLeft}}
{{toptitleRight}}
{{selectTitle}}
{{toptitleLeft}}
{{index}}
{{select_list_per.name}}
Time
{{showName}}
{{weixin_name}}
X
{{listname}}
Loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.headline}}
{{storydata.create_time}}
{{storydata.headline}}
{{storydata.create_time}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
loading
The End
Network Errors Please Retry
Akeso Announced Completion of Patient Enrollment in Phase 3 Trial of Ivonescimab (PD-1/VEGF) versus Pembrolizumab in First-line PD-L1 Positive Advanced NSCLC
2023-08-29 20:00
ProfoundBio to Participate in the 21st Annual Morgan Stanley Conference
2023-08-28 20:00
Harbour BioMed Announces 2023 Interim Results
2023-08-28 17:08
Harbour BioMed Announces US IND Clearance of Its First ADC Program HBM9033 in Solid Tumors
2023-08-28 16:30
Specialised Therapeutics acquires commercialisation rights to new oral MND therapy
2023-08-28 04:00
First participant treated at the highest dose level in Clarity's theranostic prostate cancer trial
2023-08-25 20:58
Akeso Announced that Ivonescimab Granted Priority Review of NDA by China NMPA
2023-08-25 20:00
Tigermed Reports 2023 Interim Results
2023-08-25 18:39
GC Biopharma to Produce Cholera Vaccines Jointly with Eubiologics
2023-08-25 15:14
Akeso Announced NDA Acceptance of IL-12/lL-23 Monoclonal Antibody Ebdarokimab for Moderate-to-severe Plaque Psoriasis by China NMPA
2023-08-24 20:00
111, Inc. Announces Second Quarter 2023 Unaudited Financial Results
2023-08-24 14:00
PeptiGrowth Inc. and Orizuru Therapeutics, Inc. Enter into Joint Development of Novel Synthetic Peptide Based Growth Factor
2023-08-24 09:51
Samsung Biologics appoints new leadership to oversee quality and regulatory affairs
2023-08-24 07:59
Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill
2023-08-23 17:00
ImmVira Appoints Howard L. Kaufman, M.D. as Consulting Medical Advisor
2023-08-23 10:51
Asieris Pharmaceuticals Unveils 2023 Semi-Annual Report, Demonstrating Initial Success of Specialty Pharma Strategy and Multi-Product Synergistic Commercialization
2023-08-22 20:58
Sanyou Biopharmaceuticals and Sinorda Biomedicine signed Strategic Cooperation Agreement for Advancing Innovative Drug Research and Development
2023-08-22 20:00
CARsgen Announced 2023 Interim Results
2023-08-22 19:30
Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China
2023-08-22 17:13
Introducing NeoMab™: GemPharmatech's Innovative Antibody Gene Humanized Mouse Model
2023-08-22 08:59
1
21
22
23
24
25
147